Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant

Sammy Huygens; Bas Oude Munnink; Arvind Gharbharan; Marion Koopmans; Bart Rijnders

doi:10.1093/cid/ciac601

Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant

Clin Infect Dis. 2023 Feb 8;76(3):e507-e509. doi: 10.1093/cid/ciac601.

Authors

Sammy Huygens¹, Bas Oude Munnink², Arvind Gharbharan¹, Marion Koopmans², Bart Rijnders¹

Affiliations

¹ Department of Internal Medicine, Section of Infectious Diseases and Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, University Medical Center, Rotterdam, The Netherlands.
² Department of Viroscience, Erasmus Medical Center, University Medical Center, Rotterdam, The Netherlands.

Abstract

Viral evolution was evaluated in 47 immunocompromised patients treated with sotrovimab. Sequencing of SARS-CoV-2 following therapy was successful in 16. Mutations associated with sotrovimab resistance were documented in 6; viral replication continued after 30 days in 5. Combination antibody therapy may be required to avoid acquired resistance in immunocompromised patients.

Keywords: Omicron; SARS-CoV-2; immunocompromised; resistance; sotrovimab.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

COVID-19*
Humans
Immunocompromised Host
SARS-CoV-2*

Substances

sotrovimab

Supplementary concepts

SARS-CoV-2 variants